Letter | Published:

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Nature Geneticsvolume 51pages202206 (2019) | Download Citation

Abstract

Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers, but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor mutational burden (TMB) may predict clinical response to ICI. To examine this association more broadly, we analyzed the clinical and genomic data of 1,662 advanced cancer patients treated with ICI, and 5,371 non-ICI-treated patients, whose tumors underwent targeted next-generation sequencing (MSK-IMPACT). Among all patients, higher somatic TMB (highest 20% in each histology) was associated with better overall survival. For most cancer histologies, an association between higher TMB and improved survival was observed. The TMB cutpoints associated with improved survival varied markedly between cancer types. These data indicate that TMB is associated with improved survival in patients receiving ICI across a wide variety of cancer types, but that there may not be one universal definition of high TMB.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Data availability

Data necessary to reproduce the figures are provided in Supplementary Data. All data are publicly available at http://www.cbioportal.org/study?id=tmb_mskcc_2018.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Callahan, M. K., Postow, M. A. & Wolchok, J. D. Targeting T cell co-receptors for cancer therapy. Immunity 44, 1069–1078 (2016).

  2. 2.

    Powles, T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391, 748–757 (2018).

  3. 3.

    Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017).

  4. 4.

    Cohen, E. E. et al. LBA45_PR Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial. Ann. Oncol. 28, mdx440.040 (2017).

  5. 5.

    Bendell, J. et al. LBA-004 Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab + cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. Ann. Oncol. 29, mdy208.003 (2018).

  6. 6.

    Gibney, G. T., Weiner, L. M. & Atkins, M. B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17, e542–e551 (2016).

  7. 7.

    Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).

  8. 8.

    Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).

  9. 9.

    Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).

  10. 10.

    Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016).

  11. 11.

    Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016).

  12. 12.

    Cheng, D. T. et al. Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251–264 (2015).

  13. 13.

    Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).

  14. 14.

    Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).

  15. 15.

    Jordan, E. J. et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 7, 596–609 (2017).

  16. 16.

    Janjigian, Y. Y. et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 8, 49–58 (2018).

  17. 17.

    Rizvi, H. et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J. Clin. Oncol. 36, 633–641 (2018).

  18. 18.

    Bouffet, E. et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol. 34, 2206–2211 (2016).

  19. 19.

    McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463–1469 (2016).

  20. 20.

    Frampton, G. M. et al. Assessment of tumor mutation burden from >60,000 clinical cancer patients using comprehensive genomic profiling. J. Clin. Oncol. 34, 11558 (2016).

  21. 21.

    Johnson, D. B. et al. Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol. Res. 4, 959–967 (2016).

  22. 22.

    Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).

  23. 23.

    Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).

  24. 24.

    Roszik, J. et al. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 14, 168 (2016).

  25. 25.

    Chowell, D. et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 62, eaao4572 (2017).

  26. 26.

    Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551, 512–516 (2017).

  27. 27.

    Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).

  28. 28.

    Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).

  29. 29.

    Segal, N. H. et al. Epitope landscape in breast and colorectal cancer. Cancer Res. 68, 889–892 (2008).

  30. 30.

    Verdegaal, E. M. E. et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature 536, 91–95 (2016).

  31. 31.

    Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).

Download references

Acknowledgements

We gratefully acknowledge the patients in this study and their families. We thank M. Gonen for statistical advice. We thank members of the Molecular Diagnostics Service in the Department of Pathology and the Marie-Josée and Henry R. Kravis Center for Molecular Oncology. We acknowledge funding sources, including the AACR-AstraZeneca Immunotherapy Fellowship (R.M.S.), Pershing Square Sohn Cancer Research grant (T.A.C.), the PaineWebber Chair (T.A.C.), Stand Up To Cancer (T.A.C.), NIH R01 CA205426, the STARR Cancer Consortium (T.A.C.), NCI R35 CA232097 (T.A.C.), Precision Immunotherapy Kidney Cancer Fund (T.A.C., R.J.M.), The Frederick Adler Fund, Cycle for Survival, NIH K08 DE024774 and R01 DE027738 (L.G.T.M.), and MSKCC through NIH/NCI Cancer Center Support Grant (P30 CA008748).

Author information

Author notes

  1. These authors contributed equally: Robert M. Samstein, Chung-Han Lee, Alexander N. Shoushtari, Matthew D. Hellmann.

  2. These authors jointly supervised this work: Nadeem Riaz, David B. Solit, Timothy A. Chan, Luc G. T. Morris.

Affiliations

  1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    • Robert M. Samstein
    • , David A. Barron
    • , Christopher A. Barker
    • , Nancy Lee
    • , Nadeem Riaz
    •  & Timothy A. Chan
  2. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    • Robert M. Samstein
    • , David A. Barron
    • , Emmet J. Jordan
    • , Sviatoslav M. Kendall
    • , Marc Ladanyi
    • , Nadeem Riaz
    • , David B. Solit
    • , Timothy A. Chan
    •  & Luc G. T. Morris
  3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    • Chung-Han Lee
    • , Alexander N. Shoushtari
    • , Matthew D. Hellmann
    • , Yelena Y. Janjigian
    • , Robert J. Motzer
    • , Martin H. Voss
    • , Jonathan Rosenberg
    • , Gopa Iyer
    • , Dean F. Bajorin
    • , Jamie E. Chaft
    • , Charles M. Rudin
    • , Gregory J. Riely
    • , Shrujal Baxi
    • , Alan L. Ho
    • , David G. Pfister
    • , Jedd D. Wolchok
    • , William D. Tap
    • , Mrinal M. Gounder
    • , Sandra P. D’Angelo
    • , Leonard Saltz
    • , Zsofia K. Stadler
    • , Howard I. Scher
    • , Jose Baselga
    • , Pedram Razavi
    • , Christopher A. Klebanoff
    • , Rona Yaeger
    • , Neil H. Segal
    • , Geoffrey Y. Ku
    • , Michael F. Berger
    •  & David B. Solit
  4. Department of Medicine, Weill Cornell Medical Center, New York, NY, USA

    • Chung-Han Lee
    • , Alexander N. Shoushtari
    • , Matthew D. Hellmann
    • , Yelena Y. Janjigian
    • , Robert J. Motzer
    • , Martin H. Voss
    • , Jonathan Rosenberg
    • , Gopa Iyer
    • , Dean F. Bajorin
    • , Jamie E. Chaft
    • , Charles M. Rudin
    • , Gregory J. Riely
    • , Shrujal Baxi
    • , Alan L. Ho
    • , David G. Pfister
    • , Jedd D. Wolchok
    • , William D. Tap
    • , Mrinal M. Gounder
    • , Sandra P. D’Angelo
    • , Leonard Saltz
    • , Zsofia K. Stadler
    • , Howard I. Scher
    • , Jose Baselga
    • , Pedram Razavi
    • , Christopher A. Klebanoff
    • , Rona Yaeger
    • , Neil H. Segal
    •  & Geoffrey Y. Ku
  5. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    • Ronglai Shen
  6. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    • Ahmet Zehir
    • , Hikmat A. Al-Ahmadie
    • , Marc Ladanyi
    •  & Michael F. Berger
  7. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    • Antonio Omuro
    •  & Thomas J. Kaley
  8. Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    • Sviatoslav M. Kendall
    • , Ingo K. Mellinghoff
    • , Lisa M. DeAngelis
    • , Nadeem Riaz
    • , Timothy A. Chan
    •  & Luc G. T. Morris
  9. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    • A. Ari Hakimi
    • , Paul Russo
    • , Bernard H. Bochner
    • , Richard J. Wong
    • , Philip H. Gutin
    • , Cameron W. Brennan
    • , Viviane Tabar
    • , Charlotte E. Ariyan
    • , Ronald P. DeMatteo
    •  & Luc G. T. Morris
  10. Department of Medicine, Columbia University Medical Center, New York, NY, USA

    • Naiyer A. Rizvi

Authors

  1. Search for Robert M. Samstein in:

  2. Search for Chung-Han Lee in:

  3. Search for Alexander N. Shoushtari in:

  4. Search for Matthew D. Hellmann in:

  5. Search for Ronglai Shen in:

  6. Search for Yelena Y. Janjigian in:

  7. Search for David A. Barron in:

  8. Search for Ahmet Zehir in:

  9. Search for Emmet J. Jordan in:

  10. Search for Antonio Omuro in:

  11. Search for Thomas J. Kaley in:

  12. Search for Sviatoslav M. Kendall in:

  13. Search for Robert J. Motzer in:

  14. Search for A. Ari Hakimi in:

  15. Search for Martin H. Voss in:

  16. Search for Paul Russo in:

  17. Search for Jonathan Rosenberg in:

  18. Search for Gopa Iyer in:

  19. Search for Bernard H. Bochner in:

  20. Search for Dean F. Bajorin in:

  21. Search for Hikmat A. Al-Ahmadie in:

  22. Search for Jamie E. Chaft in:

  23. Search for Charles M. Rudin in:

  24. Search for Gregory J. Riely in:

  25. Search for Shrujal Baxi in:

  26. Search for Alan L. Ho in:

  27. Search for Richard J. Wong in:

  28. Search for David G. Pfister in:

  29. Search for Jedd D. Wolchok in:

  30. Search for Christopher A. Barker in:

  31. Search for Philip H. Gutin in:

  32. Search for Cameron W. Brennan in:

  33. Search for Viviane Tabar in:

  34. Search for Ingo K. Mellinghoff in:

  35. Search for Lisa M. DeAngelis in:

  36. Search for Charlotte E. Ariyan in:

  37. Search for Nancy Lee in:

  38. Search for William D. Tap in:

  39. Search for Mrinal M. Gounder in:

  40. Search for Sandra P. D’Angelo in:

  41. Search for Leonard Saltz in:

  42. Search for Zsofia K. Stadler in:

  43. Search for Howard I. Scher in:

  44. Search for Jose Baselga in:

  45. Search for Pedram Razavi in:

  46. Search for Christopher A. Klebanoff in:

  47. Search for Rona Yaeger in:

  48. Search for Neil H. Segal in:

  49. Search for Geoffrey Y. Ku in:

  50. Search for Ronald P. DeMatteo in:

  51. Search for Marc Ladanyi in:

  52. Search for Naiyer A. Rizvi in:

  53. Search for Michael F. Berger in:

  54. Search for Nadeem Riaz in:

  55. Search for David B. Solit in:

  56. Search for Timothy A. Chan in:

  57. Search for Luc G. T. Morris in:

Contributions

R.M.S., R.S., T.A.C., N.R. and L.G.T.M. performed the analyses. C.-H.L., A.N.S., M.D.H., Y.Y.J., D.A.B., S.M.K. and E.J.J. provided clinical annotations. A.Z., M.F.B., D.B.S., M.L. and J.B. established the assays and coordinated data collection. C.-H.L., A.N.S., M.D.H., Y.Y.J., R.J.M., G.J.R., C.A.B., S.B., P.R., A.O., H.A.A., J.R., D.F.B., A.A.H., B.H.B., M.H.V., C.M.R., H.I.S., A.L.H., D.G.P., N.L., R.J.W., V.T., P.H.G., C.W.B., L.M.D., I.K.M., J.E.C., R.Y., N.H.S., R.P.D., L.S., J.D.W., C.E.A., Z.K.S., W.D.T., M.M.G., N.A.R., S.P.D., J.B., P.R., G.Y.K., T.J.K., C.A.K., G.I. and D.B.S. contributed to sample acquisition and patient recruitment. L.G.T.M., D.B.S., N.R. and T.A.C. supervised the study. L.G.T.M., T.A.C., C.-H.L., A.N.S., M.D.H. and R.M.S. wrote the manuscript with contributions from all authors.

Competing interests

R.M.S., T.A.C. and L.G.T.M. are inventors on a provisional patent application (62/569,053) filed by Memorial Sloan Kettering (MSK) relating to the use of TMB in cancer immunotherapy. M.D.H., N.A.R. and T.A.C. are inventors on a PCT patent application (PCT/US2015/062208) filed by MSK relating to the use of TMB in lung cancer immunotherapy. MSK and the inventors may receive a share of commercialization revenue from license agreements relating to these patent applications. C.-H.L. received research funding from Eisai, BMS, Exelixis, Pfizer and Calithera, and consulting fees from Exelixis and Eisai. A.N.S. has received research support from Bristol Myers Squibb, Immunocore, Astra-Zeneca and Xcovery and serves on the advisory board for Bristol Myers Squibb, Immunocore and Castle Biosciences; he also receives royalties from UpToDate. M.D.H. receives research funding from Bristol-Myers Squibb and is a paid consultant to Merck, Bristol-Myers Squibb, AztraZeneca, Genentech/Roche, Janssen, Nektar, Syndax, Mirati and Shattuck Labs. Y.Y.J. received research funding from Boehringer Ingelheim, Bayer, Genentech/Roche, Bristol-Myers Squibb, Eli Lilly and Merck, and served on advisory boards for Merck Serono, Bristol-Myers Squibb, Eli Lilly, Pfizer, Bayer, Imugene and Merck. S.B. currently works for Flatiron Health, which is a for-profit company. R.J.M. received research support from Pfizer, Genentech/Roche, Bristol Myers Squibb and Eisai, and consulting fees from Pfizer, Genentech/Roche, Merck, Incyte, Novartis, Eisai and Exelixis. M.H.V. received commercial research grants from Bristol-Myers Squibb and Genentech/Roche; honoraria from Novartis; travel/accommodation from Eisai, Novartis and Takeda; consultant/advisory board member for Alexion Pharmaceuticals, Bayer, Calithera Biosciences, Corvus Pharmaceuticals, Exelixis, Eisai, GlaxoSmithKline, Natera, Novartis and Pfizer. J.R. receives consulting fees from Merck, AstraZeneca, Bristol-Myers Squibb, EMD-Serono, Roche/Genentech, Sanofi, Seattle Genetics, Agensys, Bayer, Inovio, Lilly, Adicet Bio, Sensei, Chugai and Inovio. B.H.B. receives consulting fees from Genentech. G.J.R. received research funding from Novartis, Roche/Genentech, Millennium, GlaxoSmithKline, Pfizer, Infinity Pharmaceuticals and Takeda, and received travel expense compensation from Merck. A.L.H. receives research funding from Eisai, Bristol-Myers Squibb, Kura Oncology, AstraZeneca, Genentech Roche, Celldex, Pfizer, Lilly and Bayer; consulting fees from Bristol-Myers Squibb, Merck, Novartis, AstraZeneca, Regeneron, Sanofi Aventis, Sun Pharmaceuticals, Eisai, Genentech/Roche, Genzyme and Ayala Pharmaceuticals; and travel fees from Ignyta and Kura Oncology. C.A.B. receives research funding from Merck, Amgen and Bristol-Myers Squibb. J.D.W. was a consultant for Adaptive Biotech, Amgen, Apricity, Array BioPharma, Ascentage Pharma, Beigene, Bristol-Myers Squibb, Celgene, Chugai, Elucida, Eli Lilly, F Star, Genentech, Imvaq, Kleo Pharma, MedImmune, Merck, Neon Therapuetics, Ono, Polaris Pharma, Polynoma, Psioxus, Puretech, Recepta, Trienza, Sellas Life Sciences, Serametri, Surface Oncology and Syndax; received research support from Bristol-Myers Squibb, Medimmune, Merck Pharmaceutical, and Genentech; and holds equity in Potenza Therapeutics, Tizona Pharmaceuticals, Adaptive Biotechnologies, Elucida, Imvaq, Beigene and Trienza. J.B. is on the Board of Directors for Varian Medical Systems, Bristol-Myers Squibb and Foghorn, and is a past board member of Grail, Aura Biosciences and Infinity Pharmaceuticals. He has performed consulting and/or advisory work for Grail, PMV Pharma, ApoGen, Juno, Roche, Lilly, Novartis and Northern Biologics. He has stock or other ownership interests in PMV Pharma, Grail, Juno, Varian, Foghorn, Aura, Infinity and ApoGen, as well Tango and Venthera, for which he is a cofounder. He has previously received honoraria and/or travel expenses from Roche, Novartis and Lilly. G.Y.K. received research funding and consulting fees from AstraZeneca, Bristol-Myers Squibb and Merck. I.K.M. reports research funding from GE and consulting/speaker fees from Agios Pharmaceuticals, Debiopharm Group, Roche, Merck, Puma Biotechnology and Deciphera Pharmaceuticals. W.D.T. reports personal fees from Eli Lilly, personal fees from EMD Serono, personal fees from Novartis, personal fees from Eisai, personal fees from Janssen, personal fees from Immune Design, personal fees from Adaptimmune, personal fees from Daiichi Sankyo, personal fees from Blueprint, personal fees from Loxo, personal fees from GlaxoSmithKline and personal fees from Agios Pharmaceuticals and from Plexxikon Pharmaceuticals, outside the submitted work. In addition, W.D.T. has a patent (Companion Diagnostic for CDK4 inhibitors–14/854,329) pending to MSKCC/SKI, and a patent (Methods of Treating Metastatic Sarcoma using Talimogene Laherparepvec (T-Vec) and Pembrolizumab Combination Therapy—62/671,625) pending to MSKCC/SKI, and Scientific Advisory Board—Certis Oncology Solutions, stock ownership; Scientific Advisory Board—Atropos Therapeutics, stock ownership. C.M.R. has consulted on oncology drug development with AbbVie, Amgen, Ascentage, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Genentech/Roche, Harpoon, Loxo, Pharmamar and Seattle Genetics. V.T. is a cofounder and consultant for BluRock Therapeutics. N.A.R. received consulting fees from Merck, AstraZeneca, Roche, Bristol-Myers Squibb, Novartis, Pfizer, Lilly, Abbvie, Merck KGaA, Regeneron and Janssen; is a cofounder and shareholder in Gritstone Oncology; and serves on the advisory board or Neogenomics, OncoMed and Bellcum. M.L. has received ad hoc advisory board compensation from AstraZeneca, Bristol-Myers Squibb, Takeda and Bayer, and research support from LOXO Oncology and Helsinn Healthcare. M.F.B. received research support from Illumina and consulting fees from Roche. D.B.S. received honoraria/consulted for Pfizer, Loxo Oncology, Illumina, Intezyne and Vivideon Therapuetics. N.R. receives research support from Bristol-Myers Squibb and Pfizer and speakers fees from Illumina. T.A.C. is a cofounder of Gritstone Oncology and holds equity. T.A.C. holds equity in An2H. T.A.C. acknowledges grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H and Eisai. T.A.C. has served as an advisor for Bristol-Myers Squibb, Illumina, Eisai and An2H. MSK has licensed the use of TMB for the identification of patients that benefit from immune checkpoint therapy to PGDx. MSK and T.A.C. receive royalties as part of this licensing agreement. L.G.T.M. received consulting fees from Rakuten Aspyrian and speaker fees from Physician Educational Resources.

Corresponding authors

Correspondence to David B. Solit or Timothy A. Chan or Luc G. T. Morris.

Supplementary information

  1. Supplementary Text and Figures

    Supplementary Figures 1–11 and Supplementary Tables 1 and 2

  2. Reporting Summary

  3. Supplementary Data

    Data file containing patient-level data for ICI- and non-ICI-treated patients

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/s41588-018-0312-8

Further reading